ISEE-RCC study
Key facts
- Where
- Nijmegen, HollandiaSee the site
- Phase
- 3. fázis
Where in Hollandia
- Stichting Radboud Universitair Medisch CentrumNijmegen, HollandiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Stichting Radboud universitair medisch centrum
- Trial code
- EU 2024-514181-39-00
- Record updated
- 2026. május 18.
- Original description
This explorative study aims to investigate and compare (both visually and semi-quantitatively) the tumor detection rates of 68Ga-gozetotide (PSMA) PET and 89Zr-DFO-girentuximab PET in patients suspected of having primary, recurrent or metastatic ccRCC.Read full original descriptionShow less
Intrapatient comparison of 68Ga-gozetotide (PSMA) PET and 89Zr-girentuximab PET in clear cell renal cell carcinoma (ISEE-RCC)
This explorative study aims to investigate and compare (both visually and semi-quantitatively) the tumor detection rates of 68Ga-gozetotide (PSMA) PET and 89Zr-DFO-girentuximab PET in patients suspected of having primary, recurrent or metastatic ccRCC.
Inclusion: ≥ 18 years; Suspicion of metastatic ccRCC on conventional contrast-enhanced CT (performed max. 4 weeks prior to the PET scan). Diagnosis may or may not be proven by biopsy prior to inclusion in the study. Primary tumor may or may not be in place.
Exclusion: Administration of tyrosine kinase inhibitors within 1 month prior to inclusion; Administration of a radioisotope within 10 physical half-lives prior to study enrollment; Possibility of pregnancy (anamnestic, if ambiguity; a pregnancy test will be conducted prior to the PET/CT) or lactation; History of a CAIX-negative, PSMA negative or non-clear cell RCC; Second active malignancy (except basal-cell carcinoma); Known hypersensitivity or formation of human anti-chimeric antibodies (HACA) against girentuximab or DFO; Renal insufficiency with GFR ≤ 45 mL/min/1.73m2; No verbal and written command of Dutch language.